15.07.2010 • NewsNovartisgender-bias trial

Novartis in $175 Million Gender Bias Settlement

Novartis has agreed to pay $175 million to settle a class-action lawsuit accusing the Swiss drugmaker of discriminating against 5,600 current and former female employees.

The settlement was announced less than two months after a Manhattan jury ordered Novartis to pay $250 million in punitive damages, after a six-week trial. That jury concluded the company's U.S. unit, Novartis Pharmaceuticals, engaged in a pattern of discrimination between 2002 and 2007.

Lawyers for the plaintiffs said it was the largest U.S. gender discrimination case ever to go to trial. In a joint statement with the plaintiffs' lawyers, Novartis said it will pay $152.5 million to eligible class members and pay an additional $22.5 million to improve companywide complaint processes, oversight and performance assessment.

The settlement requires court approval. U.S. District Judge Colleen McMahon scheduled a Nov. 19 hearing to consider whether to approve it.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.